SIRPA and neoplasm: For example, Ho et al. developed an engineered, high-affinity, CD47 variant (termed Vecro-CD47), which could remarkably increase the affinity to wild-type (WT) SIRPα and disrupt the CD47-SIRPα interaction, thereby promoting macrophage phagocytosis of tumor cells (Ho et al., 2015).